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A B S T R A C T
N-acetyl glutamate synthase (NAGS) deficiency is the rarest urea cycle defect presenting as neonatal onset life-
threatening hyperammonemia. We report here a family history of severe NAGS deficiency: after the index-case
with severe hyperammonemia, one patient benefited from antenatal diagnosis, and from primary care at birth,
another one was diagnosed at 2-days and immediately treated with carbaglumic-acid. Finally, we report ex-
cellent tolerance to long-term carbaglumic-acid treatment, with no side effects, and healthy neurological and
psychomotor development.
1. Introduction
N-acetyl glutamate synthase (NAGS) deficiency is an autosomal
recessive disease that usually presents as neonatal onset life-threatening
hyperammonemia. NAGS catalyzes the formation of N-acetyl glutamate
by the combination of glutamate and N-acetyl CoA. This molecule ac-
tivates, in an allosteric manner, carbamoylphosphate synthetase I
(CPSI), which is the first and rate-limiting enzyme of the urea cycle.
This enzyme combines ammonia with bicarbonate to produce carba-
moyl-phosphate. High plasma ammonia, glutamine, and glutamate, and
barely detectable citrulline concentrations characterize NAGS defi-
ciency [1] [2] [3] [4].
Severe NAGS deficiencies entailing the complete lack of the enzyme
lead to severe neonatal hyperammonemia; late-onset presentations re-
lated to a partial lack of the enzyme have been reported in infancy,
childhood, and adulthood [7]. All patients present a physiological
adaptation to extra-uterine life, and neurological deterioration appears
within a few hours to a few months. NAGS deficiency is the only urea
cycle disorder that is curable. This disease is currently treatable using
carbaglumic acid (Carbaglu®), an analog of N-acetyl glutamate, and a
low protein diet when initiating the treatment [5]. Management of
hyperammonemia is challenging in the acute phase.
We report here a family with severe NAGS deficiency within an
extended inbred family. We identified three patients with a complete
deficiency (homozygous for a null allele), one patient heterozygous for
this variant, and numerous miscarriages and fetal deaths, probably re-
lated to the disease. This report illustrates the overall picture of the
disease, its management, and the value of early prenatal or pre-symp-
tomatic diagnosis.
2. Patients and methods
We describe infants from a sizeable inbred family of Afghan descent
(Fig. 1). All fathers were brothers, and the two mothers were sisters and
first cousins of two of the fathers. We divided the whole family into two
branches, one for each mother.
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3. Reports and results
3.1. The first branch of the family
The mother of the index case reported one neonatal death in 2004
(IV-1), a miscarriage in 2005 (IV-2), and gave birth to a healthy boy
(IV-3) in 2005. She then married a second brother among the siblings.
She gave birth in 2013 to a baby girl (IV-4) (Fig. 1; Proband), at
39 weeks' gestation after pregnancy without any particular complica-
tions. The child's birth weight was 2770 g. At the age of 2 days, the
neonate presented axial and peripheral hypotonia, weight loss of more
than 10%, with alkalosis, hyperlactatemia, and major hyper-
ammonemia (676 μmol/L; Table 1). Dialysis was immediately pro-
posed, and she was treated with sodium phenylacetate and sodium
benzoate at 250mg/kg/day (Table1). After 24 h, ammonia fell below
200 μmol/L, treatment was adjusted (sodium benzoate 200mg/kg/
day), and Carbaglu® treatment was initiated at 100mg/kg/day, with
carnitine, arginine, and B12 vitamin supplementation. Continuous
enteral nutrition without protein, with glucose and lipids, was im-
plemented (Table1). At day-5, ammonia blood concentration normal-
ized, and dietary proteins were progressively included in her regimen to
5 g per day. The plasma amino acid profile revealed a urea cycle dis-
order (Table 1), and urinary organic acid chromatography showed the
absence of orotic acid. NAGS deficiency was then suspected, and the
patient was found to be homozygous for the p. Thr439Hisfs*52
(NM_153006.2: c.1313dupG) NAGS variant, which was previously de-
scribed [6]. MRI showed a discrete T2 hyper signal on palladium, and
punctiform hyper signals on the periventricular white matter when the
child reached the age of 7months. She experienced a single decom-
pensation episode and hospitalization for varicella at one year of age.
Now aged six years, despite the massive hyperammonemia at birth, she
has normal stature, weight, and neurological development, with an
intake of 3.5 g protein/kg/day, and Carbaglu® treatment at 50mg/kg/
day.
Then, the mother reported a miscarriage in 2014 (IV-5), and in
2015, prenatal diagnosis was performed on her fetus (IV-6), who was
found to be homozygous for the p.(Thr439Hisfs*52) NAGS variant.
Hyperechogenicity of the small intestine was found during the second-
trimester ultrasound. The healthy baby girl was born by vaginal de-
livery (38 WA; birth weight 2915 g). Her blood ammonia concentration
was monitored every 6 h for three days. The neonate was treated with a
regimen with no protein, glucose, and lipids (Table1). Carbaglu® and
arginine were introduced (Table1), and the mother's milk was then
carefully re-introduced. At birth, she had normal ammonia levels, and
amino-acid chromatography performed at day one highlighted few
abnormalities presented in Table 1. She presented one decompensation
episode at the age of two months (following the administration of ni-
trogen dioxide) with a significant seizure episode. Now four years old,
she presents good stature and weight and normal neurodevelopment.
She receives a normal protein intake at 3.5 g/kg/day and Carbaglu® at
50mg/kg/day.
3.2. The second branch of the family
In the second branch of the family, the parents are also con-
sanguineous (first cousins): the father was another of the siblings
mentioned above, and the mother was the sister of the index case's
mother. These parents reported a baby girl who died abroad on day-12
from hypotonia and coma (IV-7; 2014). Her brother (IV-8) was born in
Iran in 2015 by a cesarean section (birth weight 3130 g). He presented
mild hyperammonemia at six months in a context of severe fatigue and
frequent crying (Table 1). Because he was heterozygous for the p.
(Thr439Hisfs*52) variant of NAGS, we supposed his mild hyper-
ammonemia was likely due to difficult blood sampling or delay in
processing the sample. He is now aged five years and exhibits good
stature, weight, and neurological development and has no specific
treatment or diet.
Two years late, a baby girl was born at 39 weeks' gestation (birth
weight 2844 g; IV-9) with a physiological adaptation to extra-uterine
life. No prenatal diagnosis was performed because the parents initially
failed to mention the family history to the physician until birth. At 24 h
of life, she presented moderate hyperammonemia without alkalosis or
clinical signs (Table 1). She was immediately treated with Carbaglu®,
sodium benzoate, arginine and low protein diet (Table1). Before
treatment, amino-acid chromatography was performed and presented
abnormalities of urea cycle disorders (Table 1). The genetic diagnosis
revealed homozygosity for the p.(Thr439Hisfs*52) variant of NAGS.
She was treated with Carbaglu® (50mg/kg/day), and arginine supple-
mentation (58mg/kg/day), and a low-protein regimen (2 g/kg/day) in
the early stages of treatment, which was subsequently adjusted ac-
cording to age and development. She presented an acute episode of
hyperammonemia (153 μmol/L) at 16months, during acute infectious
disease. Now aged 20months, she exhibits good stature, weight, and
neuro-developmental evolution with no protein restriction and is
Fig. 1. Pedigree of the family.
The index case is indicated by a arrow.
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treated with Carbaglu® (50mg/kg/day).
4. Discussion
We present here several patients with various features of NAGS
deficiency, the rarest urea cycle disorder, with an estimated incidence
of 1:3,500,000–7,000,000 [3]. In our description, despite major hy-
perammonemia, the index case presented a favorable long-term out-
come, mainly as a result of early care and treatment with N-carbamoyl
glutamate. Her sister had the benefit of a prenatal diagnosis enabling
management at birth to avoid hyperammonemia, without any neuro-
logical damage. To our knowledge, we report here the first prenatal
molecular diagnosis that enabled successful management from birth.
The three homozygous patients reported very few decompensations
with moderate hyperammonemia in hyper-catabolism situations (en-
dogenous protein excess, fever, or intercurrent infections). Early treat-
ment with Carbaglu® was initiated in all patients and continued over
the long term to compensate for NAGS deficiency [8,9]. Finally, we
report excellent tolerance for long-term treatment, with no side effects,
and healthy neurological and psychomotor development. However,
further studies are needed to assess the long-term outcome of these
patients.
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